Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Pasquale EB.

Nat Rev Cancer. 2010 Mar;10(3):165-80. doi: 10.1038/nrc2806. Review.

2.
3.

Tsc2-Rheb signaling regulates EphA-mediated axon guidance.

Nie D, Di Nardo A, Han JM, Baharanyi H, Kramvis I, Huynh T, Dabora S, Codeluppi S, Pandolfi PP, Pasquale EB, Sahin M.

Nat Neurosci. 2010 Feb;13(2):163-72. doi: 10.1038/nn.2477. Epub 2010 Jan 10.

4.

The EphB2 tumor suppressor induces autophagic cell death via concomitant activation of the ERK1/2 and PI3K pathways.

Kandouz M, Haidara K, Zhao J, Brisson ML, Batist G.

Cell Cycle. 2010 Jan 15;9(2):398-407. Epub 2010 Jan 2.

PMID:
20046096
5.

Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells.

Jørgensen C, Sherman A, Chen GI, Pasculescu A, Poliakov A, Hsiung M, Larsen B, Wilkinson DG, Linding R, Pawson T.

Science. 2009 Dec 11;326(5959):1502-9. doi: 10.1126/science.1176615.

6.

Targeting mTOR globally in cancer: thinking beyond rapamycin.

Shor B, Gibbons JJ, Abraham RT, Yu K.

Cell Cycle. 2009 Dec;8(23):3831-7. Epub 2009 Dec 14. Review.

PMID:
19901542
7.

InAKTivation of insulin/IGF-1 signaling by dephosphorylation.

Narasimhan SD, Mukhopadhyay A, Tissenbaum HA.

Cell Cycle. 2009 Dec;8(23):3878-84.

8.

A role for C. elegans Eph RTK signaling in PTEN regulation.

Brisbin S, Liu J, Boudreau J, Peng J, Evangelista M, Chin-Sang I.

Dev Cell. 2009 Oct;17(4):459-69. doi: 10.1016/j.devcel.2009.08.009.

9.

mTOR signaling at a glance.

Laplante M, Sabatini DM.

J Cell Sci. 2009 Oct 15;122(Pt 20):3589-94. doi: 10.1242/jcs.051011. Review. No abstract available.

10.

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer.

Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stückrath I, Weiss J, Fischer F, Michel K, Goel A, Regales L, Politi KA, Perera S, Getlik M, Heukamp LC, Ansén S, Zander T, Beroukhim R, Kashkar H, Shokat KM, Sellers WR, Rauh D, Orr C, Hoeflich KP, Friedman L, Wong KK, Pao W, Thomas RK.

Proc Natl Acad Sci U S A. 2009 Oct 27;106(43):18351-6. doi: 10.1073/pnas.0907325106. Epub 2009 Oct 5.

11.

Targeting the phosphoinositide 3-kinase pathway in cancer.

Liu P, Cheng H, Roberts TM, Zhao JJ.

Nat Rev Drug Discov. 2009 Aug;8(8):627-44. doi: 10.1038/nrd2926. Review.

12.

EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt.

Miao H, Li DQ, Mukherjee A, Guo H, Petty A, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen ML, Wang B.

Cancer Cell. 2009 Jul 7;16(1):9-20. doi: 10.1016/j.ccr.2009.04.009.

13.

Over-expression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells.

Chiu ST, Chang KJ, Ting CH, Shen HC, Li H, Hsieh FJ.

Carcinogenesis. 2009 Sep;30(9):1475-86. doi: 10.1093/carcin/bgp133. Epub 2009 May 29.

PMID:
19483190
14.

PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.

Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL.

Am J Pathol. 2009 May;174(5):1869-79. doi: 10.2353/ajpath.2009.080055.

15.

Docking motif-guided mapping of the interactome of protein phosphatase-1.

Hendrickx A, Beullens M, Ceulemans H, Den Abt T, Van Eynde A, Nicolaescu E, Lesage B, Bollen M.

Chem Biol. 2009 Apr 24;16(4):365-71. doi: 10.1016/j.chembiol.2009.02.012.

16.

New insights into mTOR signaling: mTORC2 and beyond.

Alessi DR, Pearce LR, García-Martínez JM.

Sci Signal. 2009 Apr 21;2(67):pe27. doi: 10.1126/scisignal.267pe27.

PMID:
19383978
17.

Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis.

Taddei ML, Parri M, Angelucci A, Onnis B, Bianchini F, Giannoni E, Raugei G, Calorini L, Rucci N, Teti A, Bologna M, Chiarugi P.

Am J Pathol. 2009 Apr;174(4):1492-503. doi: 10.2353/ajpath.2009.080473. Epub 2009 Mar 5.

18.

Should individual PI3 kinase isoforms be targeted in cancer?

Jia S, Roberts TM, Zhao JJ.

Curr Opin Cell Biol. 2009 Apr;21(2):199-208. doi: 10.1016/j.ceb.2008.12.007. Epub 2009 Feb 4. Review.

19.

EphA2 engages Git1 to suppress Arf6 activity modulating epithelial cell-cell contacts.

Miura K, Nam JM, Kojima C, Mochizuki N, Sabe H.

Mol Biol Cell. 2009 Apr;20(7):1949-59. doi: 10.1091/mbc.E08-06-0549. Epub 2009 Feb 4.

20.

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice.

Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM.

Cancer Cell. 2009 Feb 3;15(2):148-59. doi: 10.1016/j.ccr.2008.12.017.

Supplemental Content

Support Center